Intriguingly, mutations in MEK are less identified (melanoma 3–8%, colorectal 3%) and ERK mutations have rarely been reported as drivers in human cancers despite the well-recognized importance of ERK activation in cancer malignancy [11]. Here, MAPK1 is linked to cancer.